| Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers RL Anderson, DV Trivedi, SS Sarkar, M Henze, W Ma, H Gong, ... Proceedings of the National Academy of Sciences 115 (35), E8143-E8152, 2018 | 308 | 2018 |
| The myosin mesa and the basis of hypercontractility caused by hypertrophic cardiomyopathy mutations S Nag, DV Trivedi, SS Sarkar, AS Adhikari, MS Sunitha, S Sutton, ... Nature structural & molecular biology 24 (6), 525-533, 2017 | 202 | 2017 |
| Hypertrophic cardiomyopathy and the myosin mesa: viewing an old disease in a new light DV Trivedi, AS Adhikari, SS Sarkar, KM Ruppel, JA Spudich Biophysical reviews 10 (1), 27-48, 2018 | 145 | 2018 |
| Early-onset hypertrophic cardiomyopathy mutations significantly increase the velocity, force, and actin-activated ATPase activity of human β-cardiac myosin AS Adhikari, KB Kooiker, SS Sarkar, C Liu, D Bernstein, JA Spudich, ... Cell reports 17 (11), 2857-2864, 2016 | 93 | 2016 |
| The hypertrophic cardiomyopathy mutations R403Q and R663H increase the number of myosin heads available to interact with actin SS Sarkar, DV Trivedi, MM Morck, AS Adhikari, SN Pasha, KM Ruppel, ... Science advances 6 (14), eaax0069, 2020 | 79 | 2020 |
| Biophysical properties of human β-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathy M Kawana, SS Sarkar, S Sutton, KM Ruppel, JA Spudich Science advances 3 (2), e1601959, 2017 | 78 | 2017 |
| Effects of hypertrophic and dilated cardiomyopathy mutations on power output by human β-cardiac myosin JA Spudich, T Aksel, SR Bartholomew, S Nag, M Kawana, EC Yu, ... Journal of Experimental Biology 219 (2), 161-167, 2016 | 77 | 2016 |
| β-Cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity AS Adhikari, DV Trivedi, SS Sarkar, D Song, KB Kooiker, D Bernstein, ... Nature communications 10 (1), 2685, 2019 | 69 | 2019 |
| Unfolding of a small protein proceeds via dry and wet globules and a solvated transition state SS Sarkar, JB Udgaonkar, G Krishnamoorthy Biophysical journal 105 (10), 2392-2402, 2013 | 45 | 2013 |
| Reduced fluorescence lifetime heterogeneity of 5-fluorotryptophan in comparison to tryptophan in proteins: implication for resonance energy transfer experiments SS Sarkar, JB Udgaonkar, G Krishnamoorthy The Journal of Physical Chemistry B 115 (22), 7479-7486, 2011 | 32 | 2011 |
| Mavacamten stabilizes a folded-back sequestered super-relaxed state of β-cardiac myosin RL Anderson, DV Trivedi, SS Sarkar, M Henze, W Ma, H Gong, ... BioRxiv, 266783, 2018 | 12 | 2018 |
| Beyond the myosin mesa: a potential unifying hypothesis on the underlying molecular basis of hyper-contractility caused by a majority of hypertrophic cardiomyopathy mutations S Nag, DV Trivedi, SS Sarkar, S Sutton, KM Ruppel, JA Spudich bioRxiv, 065508, 2016 | 7 | 2016 |
| Hypertrophic cardiomyopathy mutations at the folded-back sequestered β-cardiac myosin S1-S2 and S1-S1 interfaces release sequestered heads and increase myosin enzymatic activity AS Adhikari, DV Trivedi, SS Sarkar, D Song, KB Kooiker, D Bernstein, ... BioRxiv, 537159, 2019 | 5 | 2019 |
| Hypertrophic cardiomyopathy and the myosin mesa: viewing an old disease in a new light. Biophys Rev 10: 27–48 DV Trivedi, AS Adhikari, SS Sarkar, KM Ruppel, JA Spudich | 5 | 2018 |
| The molecular basis of hypercontractility caused by the hypertrophic cardiomyopathy mutations R403Q and R663H SS Sarkar, DV Trivedi, MM Morck, AS Adhikari, SN Pasha, KM Ruppel, ... bioRxiv, 543413, 2019 | 4 | 2019 |
| Preclinical characterization of CK-4021586, a new class of cardiac myosin inhibitors for the treatment of hypertrophic cardiomyopathy SS Sarkar, JJ Hartman, DT Hwee, C Chuang, P Cremin, A deRosier, ... Biophysical Journal 122 (3), 122a, 2023 | 1 | 2023 |
| Structure and Dynamics of Molten Globular Intermediates Encountered during the Unfolding of Barstar SS Sarkar, JB Udgaonkar, G Krishnamoorthy Biophysical Journal 102 (3), 449a, 2012 | 1 | 2012 |
| Protein Folding, Unfolding, and Aggregation Processes Revealed by Rapid Sampling of Time-Domain Fluorescence SS Sarkar, A Saxena, N Dhawale, JB Udgaonkar, G Krishnamoorthy Reviews in Fluorescence 2009, 281-301, 2011 | 1 | 2011 |
| Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy JJ Hartman, DT Hwee, J Robert-Paganin, C Chuang, ER Chin, S Edell, ... Nature Cardiovascular Research, 1-14, 2024 | | 2024 |
| Aficamten, a Selective Small-Molecule Cardiac Myosin Inhibitor for the Potential Treatment of Hypertrophic Cardiomyopathy SS Sarkar, JJ Hartman, DT Hwee, C Chuang, ER Chin, S Edell, KH Lee, ... Gordon Research Conference: Cardiac Regulatory Mechanisms, 2022, 2022 | | 2022 |
James SpudichProfessor of Biochemistry, Stanford University在 stanford.edu 的电子邮件经过验证
